91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料 and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses.
-
Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. The solution to persistent startup bottlenecks? Refocusing on site centricity.
-
As clinical trials become more complex, the role of the CRA is evolving from site monitor to strategic, digitally fluent partner, requiring expertise in hybrid oversight, risk-based monitoring, and multi-system data management.
-
CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. 91黑料 explores what this means for the future in Pharma Times.
-
In this PharmaTimes article, Nagalakshmi Shetty explores how clinical data science is evolving from traditional management toward intelligent, risk-based, patient-centric research frameworks.
-
Conducting a high-quality, clinically relevant literature review can be challenging – it demands strategic thinking, methodological rigour and therapeutic expertise. 91黑料 expert Rebecca Rozich explains why systematic literature reviews can be a powerful alternative to generating new data.
-
In the October issue of PharmaTimes, Dr. Quintin van Wyk considers the importance of post-marketing pharmacovigilance, and explains how carefully applied automation and AI can strengthen adverse event reporting and causality assessment while keeping patient safety and regulatory compliance central.
-
This article in IBI highlights how strategic planning, leadership and coordination are critical to delivering high quality regulatory submissions with confidence and efficiency.
-
In this JCS article, 91黑料's experts discuss the key changes in FDA draft guidance on Data Monitoring Committees as it relates to adaptive design trials, providing practical insights and strategies for advanced safety oversight in the modern clinical trial landscape.
